Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TOP5668 is an investigational **small molecule** dihydropyrazole compound developed by **TocopheRx** as an **oral follicle stimulating hormone receptor agonist** for female infertility. It is designed as a **selective allosteric agonist** of the follicle stimulating hormone receptor, with reported lack of activity at related glycoprotein hormone receptors such as luteinizing hormone chorionic gonadotropin receptor and thyroid stimulating hormone receptor. In preclinical studies, TOP5668 was reported to be more potent than TOP5300 in stimulating estradiol production from human granulosa cells and to show follicular development activity comparable to recombinant follicle stimulating hormone in animal models. The program is intended to provide an oral alternative to injectable follicle stimulating hormone products for ovulation induction and controlled ovarian stimulation used in assisted reproduction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TOP5668.